Allergan

Last updated
Allergan plc
Company type Subsidiary
NYSE: AGN
Industry Pharmaceuticals
Predecessors Allergan, Inc. and Actavis before the 2015 tax inversion and merger
FoundedMay 16, 2013;11 years ago (2013-05-16), upon the combination of Allergan Finance, LLC (Actavis) & Warner Chilcott
March 17, 2015;9 years ago (2015-03-17) renamed to Allergan Plc upon the merger of Allergan, Inc and Actavis
HeadquartersClonshaugh Business & Technology Park, Coolock, D17 E400,
Dublin
,
Ireland
Number of locations
40 manufacturing facilities, 27 global R&D centres and marketing/sales facilities worldwide.
Area served
~100 countries
ProductsBranded pharmaceuticals
RevenueIncrease2.svg $16.089 billion (2019)
Decrease2.svg -$5.142 billion (2018)
Total assets Decrease2.svg $94.699 billion (2019)
Total equity Decrease2.svg $58.195 billion (2019)
Number of employees
17,800 (2018)
Parent AbbVie
Website www.allergan.com
Footnotes /references
[1]

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. [1] [2] [3] The company is the maker of Botox. [1]

Contents

Allergan plc was formed in March 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name. [4] [5] In 2016, Allergan sold its generic drugs business, Actavis, to Teva Pharmaceuticals for $40.5 billion. [6]

In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion. The merged company would be domiciled in the U.S. for tax purposes. [7] [8]

Global headquarters

Allergan's global headquarters are located in Dublin, Ireland. The company also maintains a significant presence in the United States, with administrative and operational headquarters located in various locations across the country, including Irvine, California and Madison, New Jersey. [9]

History

Allergan plc was created from the 2015 merger and Irish corporate tax inversion of two companies, Irish-based Actavis plc and U.S.-based Allergan, Inc. [10]

Allergan, Inc.

Allergan, Inc. headquarters in Irvine, California Allergan headquarters.jpg
Allergan, Inc. headquarters in Irvine, California

In 1948, pharmacist Gavin S. Herbert founded Allergan Pharmaceuticals, Inc. [10] In 1970, Allergan, Inc. became a public company via an initial public offering. [10] In 1977, Allergan announced plans to build a factory in Westport, Ireland. [11]

In 1980, it was acquired by SmithKline Corporation for $259 million [12] and was later spun-off by SmithKline Beecham in 1989. [13] In 1989, Allergan opened a manufacturing plant in Waco, Texas, to manufacture eye care products. [14]

In 1991, Allergan acquired the company Oculinum which manufactured products for eye muscle disorders. [15] [16] Following the acquisition, the product was renamed Botox. [15] [17] In 1996, Allergan received FDA approval for Alphagan ophthalmic solution for open-angle glaucoma and ocular hypertension. [18] In 1998, Allergan established The Allergan Foundation, a private US-based charitable foundation. [19]

In 2005, Allergan acquired Inamed which had a licensing agreement with Corneal Group Laboratoires for Juvederm products. [20] [21] [22] In 2006, Allergan gained rights to Juvederm products. [23] [24]

Actavis plc

In the spring of 1983, colleagues Allen Chao and David Hsia formed Watson Pharmaceuticals, a drug development in Libertyville, Illinois. [25] In late fall of 1983, the company moved to Corona, California, and began to develop and manufacture generic pharmaceuticals. [26] In February 1993, the company became a public company via an initial public offering. [26]

In 2011, the company moved its corporate headquarters from Corona, California, to Parsippany-Troy Hills, New Jersey. [27] [28] On October 31, 2012, Watson acquired Actavis for €4.25 billion and took the Actavis name. [29] In 2013, Actavis acquired Irish-registered Warner Chilcott for $5 billion and used the transaction to execute a corporate tax inversion to Ireland. [30] [31] In 2014, Actavis acquired Forest Laboratories for $25 billion. [32]

Acquisition by Actavis plc (2015–2019)

Allergan plc headquarters in Ireland Allergan Headquarters in Ireland (Clonsaugh Park, Coolock, Dublin).jpg
Allergan plc headquarters in Ireland

In 2015, Irish-based Actavis plc acquired U.S.-based Allergan, Inc., for $70 billion, and in effect redomiciled Allergan to Ireland in a corporate tax inversion. [4] [33] Actavis CEO Brent Saunders became the CEO of the combined company. [34] In June 2015, the company took the Allergan name. [35]

As of 2020, the company operated four facilities in Ireland. [36] [11]

2015

On July 7, 2015, the company acquired the rights to the late stage CGRP migraine portfolio of Merck & Co, as well as two experimental drugs for an upfront payment of $250 million. [37] Later that summer, the company acquired Oculeve for $125 million [38] and Naurex for an upfront payment of $560 million. [39] In October 2015, the company acquired AqueSys, developer of ocular implants for an initial payment of $300 million, [40] along with Kythera Biopharmaceuticals, a company focused on the medical aesthetics market, for $2.1 billion. [41] [42]

In late 2015, the company announced the acquisition of Northwood Medical Innovation, the developer of earFold. [43] On November 25, 2015, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder and obsessive compulsive disorder. [44]

Abandon Merger with Pfizer

On November 23, 2015, Allergan and Pfizer announced their intention to merge in a $160 billion transaction. [45] On April 5, 2016, after the Obama administration announced its plan to ban tax inversions, Pfizer terminated the acquisition and paid Allergan a $150 million breakup fee. [46] [47]

2016

In April 2016, the company announced it would partner with Heptares Therapeutics to develop a subtype-selective muscarinic agonists for Alzheimer's disease [48] [49] and announced the acquisition of Topokine Therapeutics, gaining the phase IIb/III compound XAF5 - a treatment for dermatochalasis. [50]

In August 2016, Allergan plc sold its generic drugs business to Teva Pharmaceutical Industries in a $40.5 billion deal [51] [52] and announced the acquisition of ForSight VISION5 for more than $95 million. [53]

In September 2016, CEO Saunders announced what he called a social contract to limit prices on the company's medications. [54] [55] That same month, the company acquired RetroSense Therapeutics for more than $60 million, [56] announced the acquisition of Tobira Therapeutics for approximately $1.7 billion [57] and, a day later, the acquisition of Akarna Therapeutics for $50 million. [58]

In October 2016, the company sold Anda, its generic drug distribution business, to Teva for $500 million [59] [60] and acquired Vitae Pharmaceuticals, focused on dermatology treatments, for $639 million. [59] [61] [62] That same month, the company announced it would acquire Motus Therapeutics, a developer of treatments for gastrointestinal disorders, for $200 million. [63] On November 22, 2016, the company acquired Chase Pharmaceuticals for $125 million. [64] [65]

2017-2020

In 2017, the company acquired LifeCell, a specialist in regenerative medicine, for $2.9 billion and Zeltique Aesthetics, maker of CoolSculpting, for $2.4 billion. [66] [67] [68] [69] On June 7, the company announced the acquisition of Keller Medical, a company that manufactures devices for use during breast augmentation surgery. [70] On December 12, the company announced the acquisition of Repros Therapeutics, a developer of drugs for reproductive system diseases. [71]

In September 2018, Allergan acquired the aesthetic company, Bonti, for $195 million. [72] [73]

In March 2019, the company acquired Envy Medical, Inc. [74] As of 2019, Allergan's Botox product had annual sales of nearly $4 billion. [75]

In 2018, along with several other drug manufacturers and distributors, the company was sued by several municipalities and states in the U.S. due to the manufacture of opioids, which have been abused in what has been referred to as the opioid epidemic. [76] [77]

Acquisition by AbbVie Inc. (2019-present)

In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion, [7] which would return Allergan to the U.S. for tax purposes. [8] On the announcement of the transaction, Abbvie disclosed that its 2019 net effective tax rate was 9%, but that post the acquisition, the Group's effective tax rate would rise to 13%. The merger was expected to close in 2020. [8]

On May 8, 2020, AbbVie completed its acquisition of Allergan.

Acquisition history

Illustration of the company's mergers, acquisitions, spin-offs and historical predecessors
Allergan, plc
(formerly known as Actavis until June 2015
when it adopted Allergan's name. Acquired by Abbvie June 2019)
Actavis plc

Auden Mckenzie Holdings Limited
(Acq 2015)

Durata Therapeutics
(Acq 2014)

Silom Medical Company
(Acq 2014)

Forest Laboratories
(Acq 2014)
Aptalis Pharma

Axcan Pharma

Eurand Pharmaceuticals

Furiex Pharmaceuticals Inc
(Acq 2014)

Galen
(Acq 2013)

Uteron Pharma, S.A.
(Acq 2013)

Warner Chilcott Plc
(Acq 2000)

Procter & Gamble
(Prescription drug div, Acq 2009)

Watson Pharmaceuticals

Andrx Corporation
(Acq 2006)

Arrow Group
(Acq 2009)

Eden Biodesign

Specifar Pharmaceuticals S.A.
(Acq 2011)

Ascent Pharmahealth Ltd
(Acq 2012)

Actavis Group
(Acq 2012)

Allergan, inc

Kythera Biopharmaceuticals
(Acq 2015)

MAP Pharmaceuticals Inc
(Acq 2013)

Inamed Corporation
(Acq 2006)

Allergan
(Advanced Medical Optics spun off in 2006)

Janssen-Ortho
Spun off in 2006

Abbott Laboratories
Acq 2007

Allergan, plc

Envy Medical, Inc.
(Acq 2019)

Repros Therapeutics
(Acq 2017)

Keller Medical, Inc
(Acq 2017)

Zeltiq Aesthetics Inc.
(Acq 2017)

LifeCell
(Acq 2016)

Chase Pharmaceuticals
(Acq 2016)

Motus Therapeutics
(Acq 2016)

Akarna Therapeutics
(Acq 2016)

RetroSense Therapeutics
(Acq 2016)

ForSight VISION5
(Acq 2016)

Tobira Therapeutics
(Acq 2016)

Vitae Pharmaceuticals, Inc
(Acq 2016)

Topokine Therapeutics
(Acq 2016)

Northwood Medical Innovation Ltd
(Acq 2015)

AqueSys
(Acq 2015)

Naurex Inc
(Acq 2015)

Oculeve, Inc
(Acq 2015)

Products

Allergan acquires, develops, manufactures and markets branded products in four therapeutic areas: medical aesthetics, eye care, central nervous system, and gastroenterology. The company manufactures several pharmaceutical products including Botox (botulinum toxin), Juvederm (injectable filler), CoolSculpting (cryolipolysis), Alphagan (brimonidine), Vraylar (cariprazine HCI), Linzess (linaclotide), [1] and Ubrelvy (ubrogepant). [15] [20] [66] [18] [78]

See also

Related Research Articles

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">Warner Chilcott</span> American pharmaceutical company

Warner Chilcott was a company in the pharmaceutical industry based in Rockaway, New Jersey. It was primarily focused on women's healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Mallinckrodt</span> Irish domiciled pharmaceutical

Mallinckrodt Pharmaceuticals plc is an American-Irish domiciled manufacturer of specialty pharmaceuticals, generic drugs and imaging agents. In 2017, it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid's most expensive drug.

<span class="mw-page-title-main">Tax inversion</span> Corporate relocation to a lower tax location

A tax inversion or corporate tax inversion is a form of tax avoidance where a corporation restructures so that the current parent is replaced by a foreign parent, and the original parent company becomes a subsidiary of the foreign parent, thus moving its tax residence to the foreign country. Executives and operational headquarters can stay in the original country. The US definition requires that the original shareholders remain a majority control of the post-inverted company. In US federal legislation a company which has been restructured in this manner is referred to as an "inverted domestic corporation", and the term "corporate expatriate" is also used.

<span class="mw-page-title-main">Alexion Pharmaceuticals</span> American healthcare company

Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

<span class="mw-page-title-main">AbbVie</span> American pharmaceutical company

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.

<span class="mw-page-title-main">Greenhill & Co.</span> American investment bank

Greenhill & Co., Inc. is an American investment banking advisory firm founded in 1996 in New York by Robert F. Greenhill. The firm provides advice on significant mergers, acquisitions, restructurings, financings, and capital raisings to leading corporations, partnerships, institutions and governments across a number of industries. Since its inception, Greenhill has advised on transactions valued at close to $3 trillion.

Brent Saunders (1970) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.

References

  1. 1 2 3 4 "Allergan plc 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission .
  2. ↑ Rockoff, Jonathan D. (11 February 2018). "New Tax Law Haunts Inversion Deals". The Wall Street Journal . Similarly, Allergan, a drugmaker that moved its headquarters to Ireland after a 2013 acquisition but gets about 80% of revenue in the U.S., expects the loss of deductions on intercompany loans will largely be balanced out by lower taxes on its U.S. sales.
  3. ↑ Rockoff, Jonathan D. (2018-05-30). "Allergan To Sell Businesses in Bid To Appease Shareholders". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-07.
  4. 1 2 "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune. 30 July 2015. For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud.
  5. ↑ Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal For Botox Maker". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-07.
  6. ↑ "Why Teva's $40 Billion Deal for Allergan's Generic Drugs Is Being Delayed". Fortune. Retrieved 2020-04-07.
  7. 1 2 Julia Kollewe (25 June 2019). "Botox maker Allergan bought by US drug giant for $63bn". The Guardian . Retrieved 25 June 2019.
  8. 1 2 3 Rebecca Spalding; Riley Griffin (25 June 2019). "AbbVie Strikes $63 Billion Deal for Botox Maker Allergan". Bloomberg.com. Bloomberg News . Retrieved 25 June 2019. The deal will return Allergan to the U.S., at least for tax purposes.
  9. ↑ "History of Allergan". March 2023.
  10. 1 2 3 Ramsey, Lydia. "How Allergan went from a tiny Los Angeles eye care company to the biggest takeover target of 2015". Business Insider. Retrieved 2020-04-07.
  11. 1 2 "Allergan opens new €160m biologics plant in Westport". RTÉ.ie. 2020-01-28.
  12. ↑ Federal Trade Commission Decisions. U.S. Government Printing Office. July 1980.
  13. ↑ Berkman, Leslie (July 27, 1989). "Shareholders OK SmithKline Deal Spinning Off Beckman, Allergan". Los Angeles Times .
  14. ↑ Copeland, Mike. "Allergan, with Waco plant, could be sold in $63 billion deal". WacoTrib.com. Retrieved 2020-04-07.
  15. 1 2 3 Vara, Vauhini (18 November 2014). "Billions and Billions for Botox". The New Yorker. Retrieved 2020-04-07.
  16. ↑ "Eye Drug Approved By F.D.A." The New York Times. Associated Press. 1990-01-09. ISSN   0362-4331 . Retrieved 2020-04-07.
  17. ↑ Steinert, April (31 May 2018). "Taking a chance on Botox paid off for Allergan". www.healio.com. Retrieved 2020-04-07.
  18. 1 2 "ALPHAGAN (brimonidine tartrate ophthalmic solution)" (PDF). fda.gov. 2016.
  19. ↑ "Allergan discloses economic impact of Cincinnati plant". www.bizjournals.com. Retrieved 2020-04-07.
  20. 1 2 "Inamed Says Board Approves Allergan Offer". Los Angeles Times. 2005-12-16. Retrieved 2020-04-07.
  21. ↑ "Allergan reports 15.8% increase in 2006 eye care pharmaceutical sales". www.healio.com. February 2, 2007. Retrieved 2020-04-07.
  22. ↑ "e10vk - Allergan, Inc". www.sec.gov. Retrieved 2020-04-07.
  23. ↑ "Allergan buys Groupe Corneal for $217M - Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2020-04-07.
  24. ↑ "FDA staff says Allergan's new dermal filler effective". Reuters. 2013-04-30. Retrieved 2020-04-07.
  25. ↑ "Pharmaceutical leader and Purdue alumnus brings expertise to Purdue-based contract drug manufacturing organization". www.purdue.edu. Purdue News Service. Retrieved 2020-04-07.
  26. 1 2 "Prescription for Success : Drug Maker Watson Thrives in Crowded Generic Market". Los Angeles Times. 1996-06-12. Retrieved 2020-04-07.
  27. ↑ Todd, Susan (January 30, 2012). "Generic drug maker Watson opening research operations in North Brunswick". NJ.com .
  28. ↑ "INDUSTRY: Corona pharmaceuticals plant to focus on contraceptives now". Press Enterprise. 2014-01-02. Retrieved 2020-04-07.
  29. ↑ "Watson to buy Actavis for at least 4.25 billion euros". Reuters. 2012-04-26. Retrieved 2020-04-07.
  30. ↑ "Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal". Financial Times . 20 May 2013. Actavis sought to fend off takeover threats by purchasing Dublin-based rival Warner Chilcott in a $5bn deal designed to turn it into the world's third-largest generic drug company by sales. The agreed all-stock deal, worth $8.5bn including net debt, follows recent efforts by competitors including Valeant and Mylan to acquire Actavis. Analysts said the move could spark alternative bids for Actavis or Warner Chilcott at a time of rapid consolidation in the sector. [..] The transaction will also exploit tax savings through the creation of a new Irish holding company, cutting Actavis' estimated 28 percent tax rate this year to 17 per cent and helping create annual synergies that the company said would exceed $400m.
  31. ↑ Mattioli, Dana (2014-11-17). "Actavis-Allergan Deal Paves Way for Tax Savings". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-07.
  32. ↑ Cimilluca, Dana Mattioli, Jonathan D. Rockoff and Dana (2014-02-18). "Actavis Agrees to Buy Forest Labs for $25 Billion". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-07.{{cite news}}: CS1 maint: multiple names: authors list (link)
  33. ↑ Stewart, Emily. "As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals". TheStreet. Retrieved 2020-04-07.
  34. ↑ Ramsey, Lydia. "Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here's how the Botox-maker fell out grace with investors and then became a takeover target". Business Insider. Retrieved 2020-04-07.
  35. ↑ "Actavis Officially Changes Name to Allergan". BioSpace. Retrieved 2020-04-07.
  36. ↑ "Allergan launches €145m Botox site as merger nears". independent. Retrieved 2020-04-07.
  37. ↑ Dulaney, Chelsey (July 7, 2015). "Allergan Buys Rights to Merck's Migraine Drugs" . The Wall Street Journal .
  38. ↑ "Allergan buys medical device firm Oculeve for $125m". Verdict Medical Devices. 2015-08-10. Retrieved 2020-04-08.
  39. ↑ Stahl, George (2015-07-26). "Allergan to Acquire Naurex for $560 Million Cash". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-08.
  40. ↑ "Allergan to acquire AqueSys". www.healio.com. September 4, 2015. Retrieved 2020-04-08.
  41. ↑ Bray, Chad (2015-06-17). "Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion". The New York Times. ISSN   0362-4331 . Retrieved 2020-04-08.
  42. ↑ "Form 8-K - Warner Chilcott Limited". www.sec.gov. October 2015. Retrieved 2020-04-08.
  43. ↑ "Allergan agrees to acquire earFold device for correcting prominent ears". www.healio.com. November 5, 2015. Retrieved 2020-04-08.
  44. ↑ "Allergan and Rugen Therapeutics team up on autism and OCD research". www.thepharmaletter.com. Retrieved 2020-04-08.
  45. ↑ "Pfizer seals $160bn Allergan deal to create drugs giant". BBC News . November 23, 2015.
  46. ↑ Rockoff, Jonathan (April 6, 2016). "Pfizer Walks Away From Allergan Deal" . The Wall Street Journal .
  47. ↑ Hoffman, Richard Rubin and Liz (2016-04-05). "New Rules on Tax Inversions Threaten Pfizer-Allergan Deal". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-08.
  48. ↑ "Solo again, Allergan strikes a $3.3B deal on Heptares' Alzheimer's portfolio". FierceBiotech. Retrieved 2020-04-08.
  49. ↑ "Form 10-Q - ALLERGAN PLC". September 30, 2016.
  50. ↑ "Allergan Makes Another Deal, Bags Boston's Topokine for $85 Million+". BioSpace. Retrieved 2020-04-08.
  51. ↑ "EX-10.66 - SETTLEMENT AGREEMENT AND MUTUAL RELEASES". www.sec.gov. Retrieved 2020-04-08.
  52. ↑ "Teva completes $40.5B Actavis deal, enters into $500M for generics distributor". www.bizjournals.com. Retrieved 2020-04-08.
  53. ↑ McElhaney, Alicia. "Allergan scoops up yet another biotech company". TheStreet. Retrieved 2020-04-08.
  54. ↑ "Behind The Scenes Of Allergan's Social Contract". www.lifescienceleader.com. Retrieved 2020-04-08.
  55. ↑ "Allergan CEO Saunders Promises Responsible Drug Prices in 'Contract'". Fortune. Retrieved 2020-04-08.
  56. ↑ "Allergan acquires RetroSense Therapeutics". www.healio.com. September 7, 2016. Retrieved 2020-04-08.
  57. ↑ Stynes, Tess (September 20, 2016). "Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal" . The Wall Street Journal .
  58. ↑ Stynes, Tess (September 21, 2016). "Allergan to Acquire U.K.'s Akarna Therapeutics" . The Wall Street Journal .
  59. 1 2 "FORM 10-K-ALLERGAN PLC - WARNER CHILCOTT LIMITED". December 2018.
  60. ↑ "Allergan to sell Anda drug distribution business to Teva". Reuters. 2016-08-03. Retrieved 2020-04-08.
  61. ↑ Hufford, Austen (2016-09-14). "Allergan to Buy Vitae Pharmaceuticals for $639 Million". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-04-08.
  62. ↑ "Allergan Completes Vitae Tender Offer". Practical Dermatology. Retrieved 2020-04-08.
  63. ↑ "Allergan to acquire Boston drug company for $200M". www.bizjournals.com. Retrieved 2020-04-08.
  64. ↑ "BRIEF-Allergan completes acquisition of Chase Pharmaceuticals". Business Insider. Retrieved 2020-04-08.
  65. ↑ "Allergan could pay $1 billion for chase pharma". RealMoney. 2016-11-25. Retrieved 2020-04-08.
  66. 1 2 "Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion". Reuters. 2017-02-13. Retrieved 2020-04-08.
  67. ↑ "Allergan completes $2.9B LifeCell acquisition". www.spglobal.com. Retrieved 2020-04-08.
  68. ↑ "Allergan Will Buy Zeltiq for $2.48 Billion". Fortune. Retrieved 2020-04-08.
  69. ↑ "BRIEF-Allergan completes Zeltiq acquisition". Business Insider. Retrieved 2020-04-08.
  70. ↑ "Allergan To Buy Medical Device Company And Breast Surgery Funnel-maker Keller Medical Inc". Fox Business - MarketWatch Pulse. 2017-06-07. Retrieved 2020-04-08.
  71. ↑ "Allergan Swoops in and Bags Troubled Repros Therapeutics". BioSpace. Retrieved 2020-04-08.
  72. ↑ "Botox Maker Allergan Buys Aesthetic Company Bonti for $195 Million Up Front". BioSpace.
  73. ↑ "Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline". BioSpace.
  74. ↑ "Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio". BioSpace.
  75. ↑ "Allergan unveils new Botox plant ahead of $63B AbbVie merger". FiercePharma. Retrieved 2020-04-08.
  76. ↑ Stempel, Jonathan (January 23, 2018). "New York City sues drug companies over opioid epidemic". Reuters .
  77. ↑ Gurman, Sadie; Mulvihill, Geoff (2 March 2018). "DOJ to Support Lawsuits Against Companies Selling Opioids". Drug Discovery & Development. Advantage Business Media. Associated Press. Retrieved 2 March 2018.
  78. ↑ Bursztynsky, Jessica (2019-12-26). "Migraine sufferers have new oral medication with FDA approval of Allergan's Ubrelvy". CNBC. Retrieved 2020-04-08.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.